Full Press Release Details
Deletion of Unauthorized Changes to Company's Website
SALT LAKE CITY, December 8, 2020 - Lipocine Inc.
(NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that an
independent contractor posted on Lipocine's website (www.lipocine.com), without authorization from Lipocine, statements suggesting
that TLANDO was approved by the U.S. Food and Drug Administration ("FDA"). TLANDO has not received final approval from
the FDA. Upon learning of the unauthorized posting to its website, Lipocine deleted the incorrect posting.
For further information:
Executive Vice President & Chief
Phone: (801) 994-7383
Phone: (617) 535-7743